Joining forces II : How COVID-19 has given Europe a new blueprint for health R&I policy

136 Aufrufe

Danke für die Bewertung! Teile es mit Deinen Freunden!

Danke für Deine Bewertung!

Published Feb 25, 2021

The COVID-19 crisis has forced the EU to take a radically new approach to R&I in health and life sciences, including new models for funding and public-private collaboration, but also broader international cooperation and data sharing. The political goal driving the Health Union package, the new agency for late-stage biomedical research – HERA, an equivalent to the US’ BARDA –, the cancer mission, the EU4Health Programme and the Pharmaceutical Strategy for Europe is clear: to strengthen Europe health industry and the EU’s capacity to respond to cross-border health emergencies. Still, the shortage of vaccines across the continent shows limitations to what the EU can do as well as the critical need to scale up manufacturing of medicines in Europe. This panel, organised in partnership with Sanofi, is convening high-level private and public stakeholders to discuss how COVID-19 has given Europe a new blueprint for health R&I policy and the remaining gaps to make Europe’s life science sector the world leader.

Kategorien: Corona Virus aktuelle Videos

Kommentare deaktiviert.

Anmelden

Joining forces II : How COVID-19 has given Europe a new blueprint for health R&I policy

Als nächstes